PURPOSE: Acute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. While non-surgical approaches have supplanted surgery as primary treatment, surgical pulmonary embolectomy (SPE) remains a vital option for select patients. We review the current management of acute PE, with a focus on surgical therapy. METHODS: A PubMed search was performed to identify literature regarding PE and treatment. Results were filtered to include the most comprehensive publications over the past decade. RESULTS: PE is stratified based on presenting hemodynamic status or degree of mechanical pulmonary arterial occlusion. Although systemic or catheter-guided fibrinolysis is the preferred first-line treatment for the majority of cases, patients who are not candidates should be considered for SPE. Studies demonstrate no mortality benefit of thrombolysis over surgery. Systemic anticoagulation is a mainstay of treatment regardless of intervention approach. Following surgical embolectomy, direct oral anticoagulants (DOACs) have been shown to reduce recurrence of thromboembolism. CONCLUSIONS: Acute PE presents with varying degrees of clinical stability. Patients should be evaluated in the context of various available treatment options including medical, catheter-based, and surgical interventions. SPE is a safe and appropriate treatment option for appropriate patients.
PURPOSE:Acute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. While non-surgical approaches have supplanted surgery as primary treatment, surgical pulmonary embolectomy (SPE) remains a vital option for select patients. We review the current management of acute PE, with a focus on surgical therapy. METHODS: A PubMed search was performed to identify literature regarding PE and treatment. Results were filtered to include the most comprehensive publications over the past decade. RESULTS:PE is stratified based on presenting hemodynamic status or degree of mechanical pulmonary arterial occlusion. Although systemic or catheter-guided fibrinolysis is the preferred first-line treatment for the majority of cases, patients who are not candidates should be considered for SPE. Studies demonstrate no mortality benefit of thrombolysis over surgery. Systemic anticoagulation is a mainstay of treatment regardless of intervention approach. Following surgical embolectomy, direct oral anticoagulants (DOACs) have been shown to reduce recurrence of thromboembolism. CONCLUSIONS: Acute PE presents with varying degrees of clinical stability. Patients should be evaluated in the context of various available treatment options including medical, catheter-based, and surgical interventions. SPE is a safe and appropriate treatment option for appropriate patients.
Authors: Gregory Piazza; Benjamin Hohlfelder; Michael R Jaff; Kenneth Ouriel; Tod C Engelhardt; Keith M Sterling; Noah J Jones; John C Gurley; Rohit Bhatheja; Robert J Kennedy; Nilesh Goswami; Kannan Natarajan; John Rundback; Immad R Sadiq; Stephen K Liu; Narinder Bhalla; M Laiq Raja; Barry S Weinstock; Jacob Cynamon; Fakhir F Elmasri; Mark J Garcia; Mark Kumar; Juan Ayerdi; Peter Soukas; William Kuo; Ping-Yu Liu; Samuel Z Goldhaber Journal: JACC Cardiovasc Interv Date: 2015-08-24 Impact factor: 11.195
Authors: James P Greelish; Marzia Leacche; Natalia S Solenkova; Rashid M Ahmad; John G Byrne Journal: J Thorac Cardiovasc Surg Date: 2011-04-09 Impact factor: 5.209
Authors: Robert C Neely; John G Byrne; Igor Gosev; Lawrence H Cohn; Quratulain Javed; James D Rawn; Samuel Z Goldhaber; Gregory Piazza; Sary F Aranki; Prem S Shekar; Marzia Leacche Journal: Ann Thorac Surg Date: 2015-07-10 Impact factor: 4.330
Authors: Eric Secemsky; Yuchiao Chang; C Charles Jain; Joshua A Beckman; Jay Giri; Michael R Jaff; Kenneth Rosenfield; Rachel Rosovsky; Christopher Kabrhel; Ido Weinberg Journal: Am J Med Date: 2018-08-11 Impact factor: 4.965
Authors: Hannah C Kulka; Andreas Zeller; Jürgen Fornaro; Walter A Wuillemin; Stavros Konstantinides; Michael Christ Journal: Dtsch Arztebl Int Date: 2021-09-17 Impact factor: 5.594
Authors: Diego Muñoz-Guglielmetti; Tim Cooksley; Shin Ahn; Carmen Beato; Mario Aramberri; Carmen Escalante; Carme Font Journal: Support Care Cancer Date: 2022-05-17 Impact factor: 3.359